Omega Therapeutics/OMGA

$3.69

2.92%
-
1D1W1MYTD1YMAX

About Omega Therapeutics

Omega Therapeutics, Inc. is a clinical-stage biotechnology company. The Company’s OMEGA platform has enabled it to identify and validate various DNA-sequence-based epigenomic, zip codes, associated with individual regulatory elements within Insulated Genomic Domains (IGDs). The Company designs and engineers its mRNA therapeutics, which are programmable and modular epigenetic medicines, called omega epigenomic controllers (OECs), to target EpiZips for precision epigenomic control. Its pipeline consists of early-stage programs that span oncology, multigenic diseases including immunology, regenerative medicine, and select monogenic diseases. The Company’s precision epigenomic control delivered by the OMEGA platform has therapeutic applicability and transformational potential, spanning across oncology, multigenic diseases including immunology, regenerative medicine and select monogenic diseases.
Ticker
OMGA
Sector
Healthcare
Trading on
NASDAQ
Industry
Biotechnology & Drugs
CEO
Mahesh Karande
Employees
116
Headquarters
Cambridge, United States

OMGA Metrics

BasicAdvanced
$203.47M
Market cap
-
P/E ratio
-$2.08
EPS
-
Beta
-
Dividend rate

What the Analysts think about OMGA

Analyst Ratings

Majority rating from 6 analysts.
Buy

Price Targets

Average projection from 6 analysts.
225.2% upside
High $15.00
Low $10.00
$3.69
Current price
$12.00
Average price target

OMGA Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
-2,775% profit margin
QuarterlyAnnual
Q3 23
QoQ growth
Revenue
$800K
14.29%
Net income
$-22.2M
-25%
Profit margin
-2,775%
-34.37%

OMGA Earnings Performance

Earnings per share (EPS)

Company profitability
Beat by 24.32%
QuarterlyAnnual
Q4 22
Q1 23
Q2 23
Q3 23
Q4 23
Actual
-$0.64
-$0.50
-$0.54
-$0.40
-
Expected
-$0.63
-$0.60
-$0.51
-$0.53
-$0.45
Surprise
1.59%
-16.19%
6.48%
-24.32%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

Buy or sell Omega Therapeutics stock

Buy or sell Omega Therapeutics stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing